🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Such studies need to have QoL assessments, the more so because it is well known how toxic regorafenib is. Not a sweaty after doxorubicin. I wonder whether patients were involved in the design of the study. It’s only a statistically significant positive study ( PFS).

Such a great pleasure to have Professor DM Thomas from Sydney UNSW Omico Australia in Amsterdam. Today The Netherlands Cancer Institute he presented his amazing work: “Moving precision oncology from research to clinical practice for rare cancers”. Nice presentations by our PhDstudents #AYA #sarcoma later on

Improving completion rates of patient-reported outcome measures in cancer clinical trials: Scoping review investigating the implications for trial designs kwnsfk27.r.eu-west-1.awstrack.me/L0/https:%2F%2…

Join us today at the CDDF workshop for the session on innovative trial designs, chaired by WinetteVanDerGraaf, including Denis Lacombe’s lecture on the EORTC TRACE platform at 15:40. Also, don’t miss Winette’s talk on "Path to Access" tomorrow at 10:30. 🔗cddf.org/events/upcomin…

So we started with xxx bokep🇬🇧 - EORTC workshop on #RareCancers in Amsterdam with Francesco Pignatti EU Medicines Agency Patients unmet needs are obvious! How can RWD and trials support evidence together? We need to think in an innovative way.

Thank you Jean-Yves Blay for your excellent talk at the xxx bokep🇬🇧 - EORTC workshop #RareCancers You last slides summarized it so well

📰The report from the EU Medicines Agency and EORTC joint workshop on patient-reported outcomes (PRO) and health-related #QualityofLife (HRQoL) data, held earlier this year, is now available. 👉Read more: ema.europa.eu/en/events/ema-… #CancerResearch #GivingVoice2Patients

💻Join us online for the EORTC #PatientDays! In the 3rd session on #ClinicalTrials we will discuss the objectives and endpoints of #oncology trials, patient involvement, pragmatic trials, HTA, and patient data control. 👉eortc.org/event/eortc-pa… #CancerResearch WinetteVanDerGraaf

We have a vacancy in our AYA Research team. JANE2 project EU. Olga Husson nki nki.nl/careers-study/…

Last week I had the pleasure to visit Tata Memorial Hospital Mumbai for the NationalCancerGrid meeting and a subsequent meeting with the great #sarcoma team discussing #precisionmedicine and challenging cases. Common practices, but also different (available) treatment options. Interesting!

With >1000 participants and >500 abstracts presented - #CTOS2024 is the biggest platform connecting anyone interested in sarcoma research and therapy. Congratulations to the Program Directors for organizing the meeting Ana Sebio Jason Sicklick, Ashleigh Guadagnolo, Odion Binitie

Dario Callegaro presenting validation of CINSARC in pts with retroperitoneal sarcoma 🔸CINSARC is prognostic for OS and DFS 🔸CINSARC and Sarculator are correlated 🔸CINSARC do not improve prognostic value of Sarculator CTOS #CTOS2024 #CTOSTweeTOS

Most awaited presentation of the year by Patrick Schöffski - BRIGTHLINE-1 trial - Brigimadlin 🆚 doxo in 1st line DDLPS ❌negative trial - no improvement in PFS 🔸mPFS 8,4 vs 7.1m HR 0.79 🔸 ORR 22 vs8.6% ⏭️what next? #CTOS2024 CTOS

Kudos to Robert Maki,MD,past President of ctos, an extraordinary person & med onc for giving the annual Nina Axelrad Lecture. Bob is a truly kind,humble,brilliant clinician-scientist. He has been a beacon for me throughout my career. “What would Bob do?” Congrats! UC Davis Department of Orthopaedic Surgery

The current and future global burden of cancer among adolescents and young adults: a population-based study Out on Lancet Oncology This study quantifies the global burden of cancer among adolescents and young adults (ages 15–39) in 2022 and projects trends through 2050. Using

⁦⁦Omico Australia⁩ very own ⁦Professor DM Thomas⁩, Cancer Institute NSW Cancer Researcher of the Year. We’re very proud